search
Back to results

Impact of Point-of-Care EID for HIV-Exposed Infants (POC-EID)

Primary Purpose

HIV/AIDS, Infant Morbidity, Pediatric HIV Infection

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Point of Care Early Infant Diagnosis
Standard of Care Early Infant Diagnosis
Sponsored by
Elizabeth Glaser Pediatric AIDS Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV/AIDS focused on measuring HIV/AIDS, Point of Care, Early infant diagnosis, Health systems, Diagnostic tools, LMIC

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Any infant who receives an EID test, either conventional or POC, for the 4-6 week EID indication at one of the study sites (which were randomly selected from project sites in country)
  • HEI under 12 weeks of age or their parents/caregivers
  • Some methods will only include HEI who test positive (medical chart extraction and longitudinal follow up)
  • Purposively selected caregivers of HEI for in-depth interviews
  • Focus groups with community members will not require participants to have sought testing for EID

Exclusion Criteria:

  • Participants not at selected study sites
  • For some methods (medical chart extraction and longitudinal follow-up), HEI who test negative
  • For qualitative component, excluded if unable to consent due to age, competence, or inability to speak any of the study languages

Sites / Locations

  • Elizabeth Glaser Pediatric AIDS Foundation
  • Elizabeth Glaser Pediatric AIDS Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard of Care Early Infant Diagnosis

Point of Care Early Infant Diagnosis

Arm Description

Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID

The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.

Outcomes

Primary Outcome Measures

Percentage of HIV exposed infants (HEI) who have received the 4-6 week EID test result by 12 weeks
The number of children for whom a sample was drawn for the 4-6-week indication receiving EID result by 12 weeks, divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing

Secondary Outcome Measures

Testing coverage for the 4-6 week indication
Number of EID samples collected for 4-6 week indication divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing
Time from sample collection for 4-6 week EID test indication to parent's/ caregiver notification
Date of sample collection to the date that results were given to care giver
Age of patient at test result notification for 4-6 week EID test indication
HEIs date of birth, date of sample collection and date of result notification to care giver
Time from test result received for 4-6 week EID test to initiation of ART, for HIV-infected infants
Date positive result received at facility to the date the result was communicated to mother and date of ART initiation
Percentage of HIV positive infants diagnosed during 4-6 week EID testing initiated on ART
Number of HIV-infected infants initiated on ART after 4-6 week EID test divided by the number of HIV-infected infants identified after 4-6 week EID test
Number of HIV-infected infants diagnosed at the 4-6 week EID with retention in care at 6 months
Total number of infants initiated on ART 6 months ago and number of active on ART at 6 months

Full Information

First Posted
January 25, 2019
Last Updated
February 3, 2021
Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Collaborators
UNITAID
search

1. Study Identification

Unique Protocol Identification Number
NCT03824067
Brief Title
Impact of Point-of-Care EID for HIV-Exposed Infants
Acronym
POC-EID
Official Title
Evaluation of the Impact of Point-of-Care Early Infant Diagnostic (EID) Testing on Timely Receipt of EID Results and Treatment Initiation in HIV-Exposed Children in Kenya and Zimbabwe
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
August 1, 2017 (Actual)
Primary Completion Date
October 30, 2019 (Actual)
Study Completion Date
October 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Collaborators
UNITAID

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This mixed methods study will utilize a randomized step-wedge design to assess the impact of point-of-care (POC) versus conventional early infant diagnosis (EID) on key outcomes including timely return of results to caregivers and time to initiation on treatment for HIV-infected infants. Data will be collected through longitudinal clinical follow-up and medical chart extraction of routine records and lab forms. Feasibility and acceptability data will be collected through interviews with mothers/caregivers of HIV-exposed infants, and community focus groups.
Detailed Description
This study seeks to evaluate the impact of point of care (POC) early infant HIV diagnosis (EID) on turn-around time from sample collection until notification of parents/caregivers of test result, linkage to care, and time to initiation of treatment, and early retention in HIV care (3-6 months) for those infected. The study will take place in two countries, Zimbabwe and Kenya, with high HIV prevalence, and where EGPAF-supported POC EID platforms are being implemented as part of a Unitaid-funded POC EID project. As part of POC program implementation activities, in each country up to 50 EGPAF-supported sites will implement POC EID platforms. These sites may be prevention of mother-to-child transmission (PMTCT) of HIV clinics, HIV clinics or multidisciplinary health facilities. Project sites have been selected as part of the program implementation. In each country, 18 sites will be randomly selected as study sites for the impact evaluation. Using a stepped wedge design, the intervention (the POC EID platforms) will be rolled out sequentially to the study facilities over three randomly-assigned time periods. Quantitative data will be derived from routine medical and laboratory charts and longitudinal tracking and follow-up of HIV-infected infants. Qualitative data on feasibility and acceptability of POC will be derived from in-depth interviews with mothers/caregivers of HIV-exposed infants at the beginning and end of the study and community focus group discussions at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, Infant Morbidity, Pediatric HIV Infection, Transmission, Perinatal Infection
Keywords
HIV/AIDS, Point of Care, Early infant diagnosis, Health systems, Diagnostic tools, LMIC

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The design of this study is a cluster-randomized stepped wedge trial. This is whereby an intervention is rolled out sequentially to the study facilities over a number of time periods. The order in which the different clusters receive the intervention is determined at random and by the end of random allocation, all facilities will have received the intervention. Testing sites (determined from the list of all project facilities excluding pilot sites) will be randomized regarding timing of POC implementation; sites that serve as "hub" sites and their associated "spoke" sites will be given the same designation. The study will use a mixed method approach in data collection, and a qualitative component will also be conducted, including interviews and focus groups.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
9539 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of Care Early Infant Diagnosis
Arm Type
Active Comparator
Arm Description
Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
Arm Title
Point of Care Early Infant Diagnosis
Arm Type
Experimental
Arm Description
The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Intervention Type
Diagnostic Test
Intervention Name(s)
Point of Care Early Infant Diagnosis
Other Intervention Name(s)
POC EID
Intervention Description
HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Intervention Type
Diagnostic Test
Intervention Name(s)
Standard of Care Early Infant Diagnosis
Other Intervention Name(s)
SOC EID
Intervention Description
Conventional laboratory based EID testing
Primary Outcome Measure Information:
Title
Percentage of HIV exposed infants (HEI) who have received the 4-6 week EID test result by 12 weeks
Description
The number of children for whom a sample was drawn for the 4-6-week indication receiving EID result by 12 weeks, divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Testing coverage for the 4-6 week indication
Description
Number of EID samples collected for 4-6 week indication divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing
Time Frame
18 months
Title
Time from sample collection for 4-6 week EID test indication to parent's/ caregiver notification
Description
Date of sample collection to the date that results were given to care giver
Time Frame
18 months
Title
Age of patient at test result notification for 4-6 week EID test indication
Description
HEIs date of birth, date of sample collection and date of result notification to care giver
Time Frame
18 months
Title
Time from test result received for 4-6 week EID test to initiation of ART, for HIV-infected infants
Description
Date positive result received at facility to the date the result was communicated to mother and date of ART initiation
Time Frame
18 months
Title
Percentage of HIV positive infants diagnosed during 4-6 week EID testing initiated on ART
Description
Number of HIV-infected infants initiated on ART after 4-6 week EID test divided by the number of HIV-infected infants identified after 4-6 week EID test
Time Frame
18 months
Title
Number of HIV-infected infants diagnosed at the 4-6 week EID with retention in care at 6 months
Description
Total number of infants initiated on ART 6 months ago and number of active on ART at 6 months
Time Frame
24 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Any infant who receives an EID test, either conventional or POC, for the 4-6 week EID indication at one of the study sites (which were randomly selected from project sites in country) HEI under 12 weeks of age or their parents/caregivers Some methods will only include HEI who test positive (medical chart extraction and longitudinal follow up) Purposively selected caregivers of HEI for in-depth interviews Focus groups with community members will not require participants to have sought testing for EID Exclusion Criteria: Participants not at selected study sites For some methods (medical chart extraction and longitudinal follow-up), HEI who test negative For qualitative component, excluded if unable to consent due to age, competence, or inability to speak any of the study languages
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emma Sacks, PhD
Organizational Affiliation
George Washington University School of Public Health
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Collins Odhiambo, MD
Organizational Affiliation
Elizabeth Glaser Pediatric Aids Foundation - Kenya
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Agnes Mahomva, MD
Organizational Affiliation
Elizabeth Glaser Pediatric Aids Foundation - Zimbabwe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jennifer Cohn, MD MPH
Organizational Affiliation
Elizabeth Glaser Pediatric AIDS Foundation
Official's Role
Study Director
Facility Information:
Facility Name
Elizabeth Glaser Pediatric AIDS Foundation
City
Nairobi
Country
Kenya
Facility Name
Elizabeth Glaser Pediatric AIDS Foundation
City
Harare
Country
Zimbabwe

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Impact of Point-of-Care EID for HIV-Exposed Infants

We'll reach out to this number within 24 hrs